Start-up with UNC ties secures $2.9M to develop blood test for cancer
Updated: Dec 9, 2017
A start-up company co-founded by UNC Lineberger researcher Andrew Wang, MD, has raised $2.9 million to commercialize a test designed to capture cancer cells circulating in the blood.
January 5, 2017
Andrew Wang, MD, is a UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.
Media Contact: Laura Oleniacz, 919-445-4219, laura_oleniacz@med.unc.edu
A start-up company co-founded by a University of North Carolina Lineberger Comprehensive Cancer Center researcher has raised its first private investment to commercialize a test designed to detect and capture tumor cells (circulating tumor cells, or CTCs) in the blood.
Andrew Wang, MD, a UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology, co-founded Capio Biosciences, Inc., to develop the test in collaboration with Seungpyo Hong, PhD, a professor at the University of Wisconsin-Madison. Read more...